IQ-AI Limited Reduced Gadolinium Approach Validated' (7871L)
RNS Number : 7871L
08 September 2023
8 September 2023
("IQ-AI" or the "Company")
Reduced Gadolinium Approach Validated with IB Neuro on 1.5T MR
Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI
Ltd (LSE: IQAI), is pleased to announce the results of a study that
validates IB Neuro's processing of reduced-dose gadolinium-based
contrast agent (GBCA) perfusion studies on 1.5T scanners.
The multi-center study, led by Dr. Mark Shiroishi, MD, Assistant
Professor of Neuroradiology and Director of Neuro-Oncology Imaging
at the Keck School of Medicine of USC, is an extension of the
foundational study published in April 2019 (Moving Towards a
Consensus DSC-MRI Protocol: Validation of A Low Flip Angle Single
Dose Option as a Reference Standard for Brain Tumors) that
validated the use of a low-dose protocol for acquiring MRI
perfusion data. In the 2019 study, it was shown that 3T MRI data
collected with 50% less GBCA could provide perfusion maps
comparable to the higher dose standard when processed using IB
IB Neuro has now been validated using this approach on 1.5T
Dynamic susceptibility contrast (DSC) MRI is the most common
approach used to measure brain tumor perfusion. Relative cerebral
blood volume (rCBV) is the most widely generated parameter map that
provides important information regarding tumor grade, prognosis,
and treatment response. IB Neuro automatically processes DSC data
using its unique contrast leakage (of GBCA) correction technology.
It is the only platform that generates quantitative output that can
be directly compared across timepoints. This study also makes IB
Neuro the only platform proven to provide accurate perfusion maps
under low-dose conditions at both 1.5T and 3T MR scanners.
"IQ-AI and our collaborators around the world continue to make
advancements towards reducing GBCA consumption," said Trevor Brown,
CEO of IQ-AI. "While our patented artificial intelligence
technology available in IB Zero G remains in active development,
this study provides an immediate option for cutting GBCA by 50% on
1.5T and 3T scanners", Brown added.
"The study demonstrates that a single dose (no preload), low
flip angle method does not compromise image quality, " said Dr.
Mark Shiroishi, MD. "This is a great added benefit for patients who
may have concerns about GBCA risks, and for administrators looking
for opportunities to curtail operational expenses".
The Directors of the Company accept responsibility for the
contents of this announcement.
For further information, please contact:
Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda
Tel: 020 7469 0930
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
About Imaging Biometrics(R) LLC: IB is a wholly owned subsidiary
of IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF) and focuses on
delivering quantitative imaging platforms and therapeutics that
transform how clinicians diagnose and treat patients more
efficiently and effectively. For more information about Imaging
Biometrics, visit the
company's website at www.imagingbiometrics.com . Follow IB on Twitter, @IQAI_IB.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact firstname.lastname@example.org or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
September 08, 2023 02:00 ET (06:00 GMT)
Historical Stock Chart
From Oct 2023 to Nov 2023
Historical Stock Chart
From Nov 2022 to Nov 2023